Amneal Pharmaceuticals Announces Q1 2026 Earnings and Acquisition of Kashiv BioSciences

Amneal Pharmaceuticals (AMRX) reported Q1 2026 earnings with net revenue of $723 million and adjusted EBITDA of $202 million, both showing significant growth. The company also announced the acquisition of Kashiv BioSciences for $750 million, aiming to expand its biosimilar portfolio and boost future revenue.

By Motley Fool Transcribing · Motley Fool · May 1, 2026, 18:00 UTC

Tickers: $AMRX

Topics: acquisition biosimilars earnings financial results revenue growth

Read the full article at Motley Fool

More World news

CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Tetra Tech Forecasts FY 2027 Revenue Between $4.425B and $4.625B Amid Backlog Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC